UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer
Background: Bladder cancer is the second most common cancer of the urinary system. Early diagnosis of this tumour and estimation of risk of future progression after initial transuretherial resection have a significant impact on prognosis. Although there are several molecular markers for the diagnosi...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2009-07, Vol.101 (1), p.98-105 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Bladder cancer is the second most common cancer of the urinary system. Early diagnosis of this tumour and estimation of risk of future progression after initial transuretherial resection have a significant impact on prognosis. Although there are several molecular markers for the diagnosis and prognosis for this tumour, their accuracy is not ideal. Previous reports have shown that UHRF1 (ubiquitin-like with PHD and ring-finger domains 1) is essential for cellular proliferation. In this study, we examined whether UHRF1 can be a novel molecular marker of bladder cancer.
Methods:
We performed real-time TaqMan quantitative reverse transcription–PCR and immunohistochemistry to examine expression levels of UHRF1 in bladder and kidney cancers.
Results:
Significant overexpression of
UHRF1
was observed in bladder cancer. The overexpression was correlated with the stage and grade of the cancer. Although
UHRF1
expression in muscle-invasive cancer was greater than in non-invasive (pTa) or superficially invasive (pT1) cancers, UHRF1 could still be detected by immunohistochemistry in these early-stage cancers. Overexpression of
UHRF1
in bladder cancer was associated with increased risk of progression after transurethral resection. High expression of
UHRF1
in kidney cancer was also observed. But the increased levels of
UHRF1
in kidney cancer were less significant compared with those in bladder cancer.
Conclusion:
Our result indicates that an immunohistochemistry-based UHRF1 detection in urine sediment or surgical specimens can be a sensitive and cancer-specific diagnostic and/or prognosis method, and may greatly improve the current diagnosis based on cytology. |
---|---|
ISSN: | 0007-0920 1532-1827 |
DOI: | 10.1038/sj.bjc.6605123 |